APOE and atherosclerosis: Anti-CD47 treatment reduces vascular inflammation in human patients and ameliorates atherosclerosis in hypercholesterolemic ApoE−/− mice by correcting defects in efferocytosis and normalizing the clearance of diseased vascular tissue, leading to the regression of atherosclerosis [178,179].